|Bid||0.00 x 6700|
|Ask||0.00 x 11200|
|Day's range||95.71 - 96.97|
|52-week range||90.00 - 115.20|
|PE ratio (TTM)||25.16|
|Earnings date||9 Nov 2017|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|
Pfizer and German partner Merck KGaA's Bavencio secures an EU approval for metastatic Merkel cell carcinoma. The company also expects to make the drug commercially available within a month.
European regulators on Thursday granted market approval for Merck KGaA and Pfizer's immuno-oncology drug Bavencio to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma. In May, ...
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the recipients of the Grant for Growth Innovation (GGI) for 2017. The winners were announced at an awards presentation meeting organized by Merck KGaA, Darmstadt, Germany during the 10th International Meeting of Pediatric Endocrinology, in Washington, United States.